BIOVAXYS TECHNOLOGY CORP - BVAXF STOCK NEWS

BioVaxys Technology Corp. has successfully closed the first tranche of its non-brokered private placement, securing gross proceeds of $200,000 from the issuance of 2,000,000 units at $0.10 each. Each unit includes one common share and one warrant, exercisable at $0.20 for 48 months. This private placement aims to raise up to $1,000,000 with the second tranche expected to close soon. Funds will be utilized for working capital, and all securities issued will be subject to a statutory hold period.

BioVaxys Technology Corp. announced a significant milestone in the development of its ovarian cancer vaccine, BVX-0918. The first tumors were surgically excised from patients and sent to BioVaxys for manufacturing process validation. Collaborations with Hospices Civils de Lyon and Deaconess Research Institute facilitate tumor sourcing for production. The vaccine relies on a process of haptenization to enhance immune recognition of cancer cells. Previous clinical trials using a first-generation vaccine demonstrated promising overall survival rates. BioVaxys aims to complete Good Manufacturing Process (GMP) production soon.

BioVaxys Technology Corp. has announced that its partner, BioElpida, has successfully created multiple OVCAR-3 cell banks, essential for the GMP manufacturing of BVX-0918, a vaccine aimed at treating platinum-resistant ovarian cancer. This step is crucial for regulatory compliance in both the EU and the US, with a Phase I study planned for later this year. The company is also collaborating with medical institutions to validate tumor collection protocols for bioproduction. The innovative vaccine platform utilizes haptenization to enhance immune response against cancer cells.

BioVaxys Technology Corp. announced progress in developing a pan-sarbecovirus vaccine in collaboration with The Ohio State University. The study focuses on BVX-1021, a booster vaccine aimed at inducing immune responses to various sarbecoviruses, including SARS-CoV-2 variants. They are preparing new recombinant SARS-1 protein to enhance study reproducibility. Results from neutralizing antibody studies are expected by late August 2022. This initiative aligns with WHO's call for enhanced vaccines against evolving strains, reflecting a critical need for effective pan-sarbecovirus solutions.

BioVaxys Technology Corp. has filed an international patent application under the Patent Cooperation Treaty (PCT) to extend its cancer vaccine platform’s protection for cervical cancer. The Vancouver-based company has partnered with Procare Health to co-develop an autologous bihaptenized cervical cancer vaccine for the EU market and to conduct an upcoming Phase I clinical study of BVX-0918 for ovarian cancer. Additionally, BioVaxys is exploring its vaccine platform for colorectal cancer.

BioVaxys Technology Corp. (BVAXF) has entered a significant agreement with Deaconess Research Institute to acquire surgically debulked tumors from Stage III/IV ovarian cancer patients. This is pivotal for validating the production process of BVX-0918, an autologous haptenized tumor cell vaccine designed for late-stage ovarian cancer. The tumor cells will undergo testing at BioElpida in France, enabling the completion of Good Manufacturing Processes and preparing for a Clinical Trial Application with the European Medicines Agency. A Phase I clinical study for BVX-0918 is expected to launch later this year.

BioVaxys Technology Corp. announced a partnership with Millipore-Sigma to produce GLP-grade BVX-1021, a vaccine aimed at the SARS1 coronavirus. This vaccine is part of ongoing research with The Ohio State University, focusing on a broad pan-sarbecovirus vaccine. The study assesses the vaccine's ability to produce virus-neutralizing antibodies against SARS-CoV-2 and related viruses. Notably, BVX-1021 is designed as a booster for individuals already vaccinated or recovered from Covid-19, with potential significant market implications as it targets a wide audience.

BioVaxys Technology Corp. announced that its haptenized SARS-CoV-2 vaccine, BVX-0320, shows no binding to the ACE2 receptor, potentially reducing cardiac risks linked to mRNA vaccines. The study indicates that BVX-0320 may prevent myocarditis while stimulating robust antibody and T cell responses. This development is part of ongoing collaborations, including a partnership with The Ohio State University. The company is advancing its vaccine and plans clinical trials in Europe.

BioVaxys Technology Corp. announced a non-brokered private placement of up to 6,666,667 units at $0.15 per unit, aiming to raise approximately $1,000,000. Each unit includes one common share and one warrant, exercisable at $0.30 for 36 months. The proceeds will be used for working capital, subject to Canadian Securities Exchange approval. BioVaxys is focused on developing vaccines and diagnostics, including a SARS-CoV-2 vaccine and an ovarian cancer vaccine, backed by several patents. The placement closing is anticipated to occur within a week.